Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority ...

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a ...

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Avidity Biosciences' AOC platform shows promising results for genetic diseases, making it a strong buy with potential upside ...

PAR Technology , a global foodservice technology company, today announces that Condado Tacos, the rapidly growing restaurant brand celebrated for its custom tacos and bold flavors, has selected PAR® ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...